Phase II clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients.
Clinical Trial
Gastrectomy
Gastric Cancer
Neoadjuvant Chemotherapy
Older Person
Phase 2
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
03
05
2023
accepted:
16
06
2023
medline:
1
9
2023
pubmed:
27
6
2023
entrez:
27
6
2023
Statut:
ppublish
Résumé
Gastrectomy with D2 dissection and adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer (LAGC) in Asia. However, administering chemotherapy with sufficient intensity after gastrectomy is challenging. Several trials demonstrated the efficacy of neoadjuvant chemotherapy (NAC). However, limited studies explored the feasibility of NAC-SOX for older patients with LAGC. This phase II study (KSCC1801) evaluated the safety and efficacy of NAC-SOX in patients with LAGC aged ≥ 70 years. Patients received three cycles of SOX The median age of 26 enrolled patients was 74.5 years. The median DI in NAC-SOX NAC-SOX
Sections du résumé
BACKGROUND
BACKGROUND
Gastrectomy with D2 dissection and adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer (LAGC) in Asia. However, administering chemotherapy with sufficient intensity after gastrectomy is challenging. Several trials demonstrated the efficacy of neoadjuvant chemotherapy (NAC). However, limited studies explored the feasibility of NAC-SOX for older patients with LAGC. This phase II study (KSCC1801) evaluated the safety and efficacy of NAC-SOX in patients with LAGC aged ≥ 70 years.
METHODS
METHODS
Patients received three cycles of SOX
RESULTS
RESULTS
The median age of 26 enrolled patients was 74.5 years. The median DI in NAC-SOX
CONCLUSIONS
CONCLUSIONS
NAC-SOX
Identifiants
pubmed: 37368093
doi: 10.1007/s10147-023-02373-3
pii: 10.1007/s10147-023-02373-3
pmc: PMC10468941
doi:
Substances chimiques
Oxaliplatin
04ZR38536J
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1166-1175Informations de copyright
© 2023. The Author(s).
Références
Surg Today. 2016 Sep;46(9):1076-82
pubmed: 26563224
Langenbecks Arch Surg. 2020 Sep;405(6):777-785
pubmed: 32617667
Oncologist. 2020 Feb;25(2):119-e208
pubmed: 32043772
Gastric Cancer. 2023 Jan;26(1):1-25
pubmed: 36342574
JAMA Oncol. 2021 Jun 1;7(6):869-877
pubmed: 33983395
Gastric Cancer. 2016 Jul;19(3):919-26
pubmed: 26474989
J Surg Oncol. 2016 Jan;113(1):36-41
pubmed: 26604064
Eur J Cancer. 2020 May;130:146-154
pubmed: 32208351
Gastric Cancer. 2022 Jan;25(1):180-187
pubmed: 34379229
World J Surg. 2019 Aug;43(8):2016-2024
pubmed: 30737551
Ann Oncol. 2015 Jan;26(1):141-148
pubmed: 25316259
J Clin Oncol. 2011 Nov 20;29(33):4387-93
pubmed: 22010012
Gastric Cancer. 2017 Mar;20(2):332-340
pubmed: 26956689
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Lancet Oncol. 2022 Feb;23(2):234-247
pubmed: 35030335
J Clin Oncol. 2021 Sep 10;39(26):2903-2913
pubmed: 34133211
J Geriatr Oncol. 2017 May;8(3):170-175
pubmed: 28119041
Gastric Cancer. 2017 Jan;20(1):175-181
pubmed: 26626800
World J Gastroenterol. 2011 Dec 21;17(47):5221-6
pubmed: 22215948
Cancer Chemother Pharmacol. 2010 May;65(6):1093-9
pubmed: 19727730
Int J Clin Oncol. 2019 Oct;24(10):1190-1196
pubmed: 31104175
Am J Cancer Res. 2021 May 15;11(5):2312-2318
pubmed: 34094687
J Geriatr Oncol. 2017 Mar;8(2):96-101
pubmed: 27856262
Pathol Oncol Res. 2015 Sep;21(4):867-73
pubmed: 25648439
Lancet Oncol. 2021 Aug;22(8):1081-1092
pubmed: 34252374
Int J Clin Oncol. 2013 Feb;18(1):10-6
pubmed: 22020563
Lancet Oncol. 2008 Mar;9(3):215-21
pubmed: 18282805
Ann Oncol. 2021 Mar;32(3):368-374
pubmed: 33278599
Lancet Oncol. 2014 Nov;15(12):1389-96
pubmed: 25439693
Cancer Treat Rev. 2021 Nov;100:102289
pubmed: 34583303
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686
Gastric Cancer. 2019 Nov;22(6):1215-1225
pubmed: 30955110
Ann Surg Oncol. 2014 Jul;21(7):2340-6
pubmed: 24604583
Lancet. 2021 Jul 3;398(10294):27-40
pubmed: 34102137
J Clin Oncol. 2019 May 20;37(15):1296-1304
pubmed: 30925125